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Abstract
Purpose Oral temozolomide is approved in many coun-
tries for malignant glioma and for melanoma in some
countries outside the USA. This study evaluated the
exposure equivalence and safety of temozolomide by
intravenous infusion and oral administration.
Methods Subjects with primary central nervous system
malignancies (excluding central nervous system lym-
phoma) received 200 mg/m
2 of oral temozolomide on days
1, 2 and 5. On days 3 and 4, subjects received 150 mg/m
2
temozolomide either as a 90-min intravenous infusion on
one day or by oral administration on an alternate day.
Results Ratiooflog-transformedmeans(intravenous:oral)
of area under the concentration–time curve and maximum
concentration of drug after dosing for temozolomide and
5-(3-methyltriazen-1-yl)imidazole-4-carboxamide (MTIC)
met exposure equivalence criteria (90% conﬁdence inter-
val = 0.8–1.25). Treatment-emergent adverse events were
consistent with those reported previously in subjects with
recurrent glioma treated with oral temozolomide, except for
mostly mild and transient injection site reactions with
intravenous administration.
Conclusions This study demonstrated an exposure equiv-
alence of a 90-min intravenous infusion of temozolomide
and an equivalent oral dose.
Keywords Temozolomide  Pharmacokinetics 
AUC  Exposure equivalence  Oral  Intravenous
Introduction
DNA alkylating agents have historically played an impor-
tant role in systemic chemotherapy for cancer, including
brain tumors. The ﬁrst-generation alkylating agent dacar-
bazine (DTIC) requires enzymatic conversion to the active
cytotoxic metabolite 5-(3-methyltriazen-1-yl)imidazole-4-
carboxamide (MTIC) in the liver [1]. There are concerns
that the therapeutic potential of DTIC in central nervous
system (CNS) malignancies is limited because MTIC may
not efﬁciently penetrate the blood–brain barrier. Temozol-
omide, an oral alkylating agent, overcomes these limita-
tions. Temozolomide is rapidly absorbed following oral
administration, with Tmax values of approximately 1 h, and
undergoes spontaneous pH-dependent hydrolysis to MTIC
at physiologic pH with a half-life (t) of approximately
1.8 h. MTIC is characterized by the formation of rate-lim-
ited pharmacokinetics (PK), with an observed in vivo half-
life similar to that of temozolomide. MTIC subsequently
degrades by pH-dependent hydrolysis to a reactive methyl-
diazonium cation and AIC (5-aminoimidazole-4-carbox-
amide). Based on data from a limited number of subjects,
the systemic bioavailability of oral temozolomide appears
to be nearly 100% [2, 3]. Additionally, in a 14C-AME
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approximately 1% of the administered dose, suggesting that
temozolomide is completely absorbed following oral
administration. [4] Because temozolomide is lipophilic, it
efﬁcientlycrossestheblood–brainbarrierandisbioavailable
to the CNS (20–30% of plasma exposure) [2, 5].
Oral temozolomide is approved in many countries for
the treatment of malignant glioma, and is approved for the
treatment of melanoma in some regions. Oral temozolo-
mide cannot be administered to all patients, speciﬁcally
patients with difﬁculty swallowing capsules. This includes:
patients with oropharyngeal dysfunction resulting from
increased intracranial pressure/brain stem involvement;
patients unable to take oral medications because of gas-
trointestinal obstruction, intractable nausea and vomiting,
or other comorbidities affecting systemic absorption of the
drug; and pediatric patients. An intravenous formulation
provides a reasonable alternative for these patients.
An exposure equivalence approach was used to develop
an intravenous formulation for temozolomide. Previous
studies in nonhuman primates [6], dogs (unpublished data)
and rats [7] demonstrated similar plasma PK proﬁles of
temozolomide following oral or intravenous administra-
tion. Based on these data, a pilot clinical study was con-
ducted to compare the PK proﬁles of equivalent doses of
temozolomide, administered orally or by a 60-min intra-
venous infusion. The study demonstrated that the area
under the curve (AUC) of oral and intravenous temozolo-
mide were similar. However, the ratio (intravenous:oral) of
maximum concentration of drug after dosing (Cmax) did not
meet the criteria for exposure equivalence. The key
parameter that required optimization was the rate of
intravenous infusion so as to better match gastrointestinal
absorption kinetics and achieve similar Cmax values to that
achieved via oral administration. Subsequently, Monte
Carlo simulations to evaluate virtual crossover exposure
equivalence trials using a population PK model derived
from a previous population study of oral temozolomide [8]
were conducted and suggested that a 90-min intravenous
infusion could achieve exposure equivalence with respect
to Cmax (unpublished data). The goal of this pivotal, ran-
domized crossover study was to examine the exposure
equivalence and safety proﬁle of a 90-min intravenous
infusion of temozolomide compared with an equivalent
oral dose.
Methods
Eligibility
Eligible subjects had a diagnosis of a primary CNS tumor
(excluding CNS lymphoma), were at least 18 years of age
and had a Karnofsky performance score of 70 of higher. All
subjects were required to have adequate hematologic,
hepatic and renal function. Subjects were excluded if they
had impaired gastrointestinal absorption, vomiting or any
other medical condition that would compromise the intake
of oral medication. Subjects were excluded if they had
received chemotherapy or biologic anticancer therapy
within 4 weeks before study entry, or mitomycin C or
nitrosourea therapy within 6 weeks before study entry.
This study was conducted in accordance with good clinical
practice (GCP) and in compliance with the World Medical
Association Declaration of Helsinki with respect to written
informed consent and the protection of rights of human
subjects.
Study design
This multicenter, open-label, randomized, crossover study
compared the PK of intravenous and oral temozolomide.
As this study was conducted in the context of treating
subjects with primary CNS malignancies, oral temozolo-
mide was administered at the highest approved dose
(200 mg/m
2) on days 1, 2 and 5. On days 3 and 4, tem-
ozolomide was administered orally on one day and by 90-
min intravenous infusion on an alternate day at a dose of
150 mg/m
2 (the approved dose of temozolomide for the
ﬁrst cycle of treatment). Subjects were assigned, according
to a computer-generated random code, to receive intrave-
nous temozolomide either on day 3 or day 4 with oral
temozolomide on an alternate day. All daily oral doses
were rounded down to the nearest 5 mg. The doses to be
administered on days 3 and 4, intravenous versus oral, were
identical. If vomiting occurred during oral dosing, the
subject was not redosed. For PK sampling on days 3 and 4,
subjects were to fast for a minimum of 8 h before each
dose of temozolomide and to continue fasting for 4 h
afterward.
The primary objective was to evaluate exposure equiv-
alence of a 90-min intravenous infusion to an equivalent
oral dose of temozolomide based on the ratio of the log-
transformed means for AUC and Cmax for both temozolo-
mide and MTIC. Based on regulatory guidelines, exposure
equivalence was deﬁned as a 90% conﬁdence interval (CI)
for the ratio of the means based on log-transformed data
within the range of 80–125% [9, 10]. Secondary end points
included local tolerability and safety. Adverse events were
graded according to National Cancer Institute Common
Terminology Criteria for Adverse Events (NCI-CTCAE)
version 3.0 over a 28-day period beginning from admin-
istration of the ﬁrst dose of temozolomide.
The PK of temozolomide and MTIC following intrave-
nous and oral administration was determined from serial
blood samples taken on days 3 and 4, just before dosing
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123(0 h), and at 0.25, 0.50, 1.00, 1.25, 1.5 (for intravenous
dose, within 5 min after the end of infusion), 1.75, 2.00,
2.50, 3.00, 4.00, 6.00 and 8.00 h after initiation of infusion
or administration of the oral dose. Plasma temozolomide
and MTIC samples were collected and procured as previ-
ously described [4, 11, 12]. Brieﬂy, blood samples for
MTIC were collected in prechilled heparinized tubes and
immediately centrifuged for 10 min at 3,000 rpm at 4C.
The resulting plasma was immediately frozen in a dry ice
methanol bath and then stored at -70C until assayed.
Blood samples for temozolomide were collected in pre-
chilled heparinized tubes and then centrifuged for 10 min
at 3,000 rpm at 4C. Immediately following centrifugation,
50 lL of 8.5% phosphoric acid was added to each mL of
plasma. Samples were then vortexed and stored at -20C
until assayed. Plasma concentrations of temozolomide and
MTIC were determined by liquid chromatography, fol-
lowed by tandem mass spectroscopy (LC-MS/MS). The
lower limit of quantitation (LLOQ) for temozolomide and
MTIC were 20 and 5 ng/mL, respectively. These methods
were validated for selectivity, sensitivity, precision and
accuracy. The stability of temozolomide in plasma after the
addition of phosphoric acid and the stability of MTIC in
plasma without phosphoric acid under various conditions
were established. The temozolomide plasma assay was
linear over the range of 20–30,000 ng/mL. The accuracy
ranged from -6.8 to -2.1%, and the precision was 9.1–
10%. The internal standard was ethazolastone. The MTIC
plasma assay was linear over the range of 5–4,000 ng/mL.
The accuracy ranged from –3.3 to 0.8% and the precision
was 3.1–9.4%. The internal standard was dacarbazine.
The study protocol was written such that data from
subjects/samples could be prospectively excluded from the
primary analysis in case of protocol violations, unsuc-
cessful dosing or possible sample procurement errors. For
instance, subjects who vomited within 4 h of oral dosing on
pharmacokinetic days, whose dose on days 3 and 4 were
not within 10% of the recommended dose, or subjects
whose intravenous infusion duration was not within 10% of
90 min were excluded. Additionally, if anomalous tem-
ozolomide or MTIC concentrations were observed (i.e.,
concentrations below LLOQ, a zero concentration between
two non-LLOQ concentrations, or an LLOQ between two
non-zero concentrations), the pH of the respective PK
sample was checked to ensure that the sample was properly
procured. If the sample was not at the recommended pH
necessary to stabilize the analyte, the sample was excluded
from analyses.
Noncompartmental analyses were conducted on indi-
vidual concentration–time data. Log-transformed PK
parameters (AUC and Cmax) for temozolomide and MTIC
were subjected to a crossover analysis of variance
(ANOVA) model, extracting the effects due to treatment,
sequence, subject within sequence and period. Assuming
an intrasubject variability (coefﬁcient of variation) of 20%
and modeling and simulation results, a target enrollment of
20 subjects was selected to provide a minimum of 90%
power for the 90% CI of the ratio of the treatment means
for derived AUC and Cmax for temozolomide and MTIC to
fall within the 80–125% conﬁdence range.
Results
Subject disposition
A total of 22 subjects were enrolled at three centers.
Subject demographics are presented in Table 1. All 22
subjects were randomized and received 5 days of treatment
with temozolomide (once-daily oral dosing of temozolo-
mide for 4 days and a single intravenous dose of tem-
ozolomide for 1 day, either on day 3 or day 4). Eleven
subjects received intravenous treatment on day 3, and 11
subjects received intravenous treatment on day 4. Phar-
macokinetic data from three subjects were excluded from
the primary analysis as per the prospectively deﬁned
exclusion criteria. Two subjects had anomalous temozol-
omide/MTIC levels [one subject had predose temozolo-
mide and MTIC concentrations that were 45 and 15%,
respectively, of the corresponding Cmax values; the other
subject had MTIC concentrations on day 4 that were at or
below assay LLOQ for all samples (in case of the latter
subject, it was determined that the samples were not pro-
cured at the appropriate pH)] and one subject had an
Table 1 Subject demographics
n = 22
Mean age, years (range) 45.8 (32–59)
Sex, n (%)
Male 12 (55)
Female 10 (45)
Race, n (%)
White 22 (100)
KPS score, n (%)
70 5 (23)
80 3 (14)
90 3 (14)
100 11 (50)
Median weight, kg (range) 80.2 (43.5–93.1)
Median height, cm (range) 170 (149–187)
Median BSA, m
2 (range) 1.735 (1.34–2.16)
KPS Karnofsky performance status, BSA body surface area
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123interrupted infusion schedule. Thus, 19 subjects were
included in the pharmacokinetic analyses.
Pharmacokinetic assessments
The Cmax, AUC and t for intravenous and orally admin-
istered temozolomide were similar and showed low inter-
subject variability (coefﬁcient of variation [CV] =
12–21%; Table 2). In contrast, the intersubject variability
for MTIC Cmax, AUC(I) and AUC(tf) ranged from 53 to
62%. Individual subject data for the Cmax of temozolomide
are shown in Fig. 1a, and the mean values follow-
ing intravenous and oral administration were 7.4 and
7.7 lg/mL, respectively. Individual subject data for the
Cmax of MTIC are shown in Fig. 1b. The individual
AUC(I) values of temozolomide and MTIC following
intravenous and oral administration are shown in Fig. 1c, d.
The ratios of the model-based (least-squares) geometric
means (intravenous:oral) for the parameters of Cmax,
AUC(I) and AUC(tf) for both temozolomide and MTIC
were within ±6% of unity (Table 3). The mean plasma
concentration–time proﬁles for temozolomide and MTIC
following temozolomide administration orally or a 90-min
intravenous infusion were identical (Fig. 2a, b). The 90%
CIs for the ratio of the log-transformed means for Cmax and
AUC (for both temozolomide and MTIC) were within the
range for exposure equivalence (80–125%). ANOVA of
log-transformed PK parameters (Cmax and AUC) did not
demonstrate any effects due to sequence of administration
or period.
Safety evaluation (n = 22)
The type and frequency of acute systemic toxicities expe-
rienced on days 3 and 4 were similar for intravenous and
oral administration (Table 4). All of these adverse events
were CTC grade 1 or 2. The most commonly reported
adverse events on days 3 and 4 were headache, dizziness,
nausea and vomiting. The most commonly reported
adverse events occurring throughout the entire 28-day
study period are also shown in Table 4. Four subjects
experienced 12 severe or life-threatening treatment-emer-
gent adverse events including hematologic toxicities
(which is the known dose-limiting toxicity for temozolo-
mide), hydrocephalus and appendicitis (both occurring in
the same subject and deemed unrelated to temozolomide),
and headache and convulsions (which were consistent with
the subject’s underlying disease and deemed unrelated to
temozolomide).
Local toxicities were evaluated by subject-reported
adverse events and a local tolerability score. Ten subjects
reported 11 injection site reactions following intravenous
administration. Nearly all events were mild and transient
(one subject reported moderate infusion site pain). Ten
events reported in nine subjects resolved on the day of the
infusion (ﬁve events with a duration of 1–6 min, four
events with a duration of 15–62 min, and one event with
a duration of 131 min), and one event resolved the fol-
lowing day. Injection site reactions included infusion/
injection site pain (n = 4), infusion site swelling (n = 1),
injection site warmth (n = 2), injection site irritation
(n = 2), injection site erythema (n = 1) and pruritus
(n = 1). No thrombophlebitis was reported. All subjects
with a local tolerability score greater than 0 also had a
treatment-emergent injection site adverse event reported.
Three subjects required local treatment for these events,
consisting of application of ice to the injection site, the
use of a pressure bandage, and/or change of injection site
location. No subject was unable to complete the infusion
or study treatment because of an adverse event at the
injection site, although one subject had the injection site
changed twice.
Table 2 Pharmacokinetic parameters of temozolomide and MTIC following intravenous and oral administration
TMZ (n = 19) MTIC (n = 19)
i.v. p.o. i.v. p.o.
t, mean hours (CV%) 1.81 (12) 1.91 (13) 1.80 (16) 1.77 (11)
Tmax, median hours (range) 1.5 (0.92–2.0) 1.0 (0.25–2.0) 1.5 (1.25–1.75) 1.0 (0.25–2.0)
tf, mean hours (CV%) 8.0 (0) 8.0 (0) 8.0 (0) 8.0 (0)
Cmax, mean lg/mL (CV%) 7.44 (21) 7.68 (19) 0.32 (61) 0.33 (62)
AUC(tf), mean lg h/mL (CV%) 23.4 (18) 22.0 (14) 0.94 (53) 0.94 (60)
AUC(I), mean lg h/mL (CV%) 25.0 (18) 23.6 (15) 1.00 (54) 1.00 (60)
Data reported as arithmetic means
TMZ, temozolomide; MTIC, 5-(3-methyltriazen-1-yl)imidazole-4-carboxamide; i.v., intravenous; p.o., oral; t1/2, half-life; CV, coefﬁcient of
variation; Tmax, time of maximal analyte concentration, tf, time of ﬁnal quantiﬁable sample; Cmax, maximum concentration of drug after dosing;
AUC(tf), area under the concentration–time curve from 0 h to time of ﬁnal quantiﬁable sample; AUC(I), area under the concentration–time curve
from 0 h to inﬁnity
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Fig. 1 Paired individual Cmax for temozolomide (a) and MTIC (b)
following intravenous (i.v.) and oral (p.o.) administration. Paired
individual AUC(I) for temozolomide (c) and MTIC (d) following
intravenous and oral administration. Cmax maximum concentration of
drug after dosing; MTIC 5-(3-methyltriazen-1-yl)imidazole-4-carbox-
amide, AUC(I) area under the concentration–time curve from 0 h to
inﬁnity
Table 3 Relative bioavailability of TMZ and MTIC following intravenous and oral administration
Mode of administration
a Intrasubject
CV (%)
Ratio estimate
c,d
i.v./p.o. (%)
90% CI, %
i.v.
b p.o.
b
MTIC (n = 19)
Cmax (lg/mL) 0.28 0.28 13 98 91–105
AUC (tf)( lg h/mL) 0.84 0.82 9 103 98–108
AUC (I) (lg h/mL) 0.89 0.86 8 103 98–108
TMZ (n = 19)
Cmax (lg/mL) 7.3 7.5 10 97 91–102
AUC (tf)( lg h/mL) 23.1 21.8 5 106 103–109
AUC (I) (lg h/mL) 24.6 23.4 5 105 102–108
TMZ, temozolomide; MTIC, 5-(3-methyltriazen-1-yl)imidazole-4-carboxamide; i.v., intravenous; p.o., oral; CV, coefﬁcient of variation; CI,
conﬁdence interval; Cmax, maximum concentration of drug after dosing; AUC (tf), area under the concentration–time curve from 0 h to time of
ﬁnal quantiﬁable sample; AUC(I), area under the concentration–time curve from 0 h to inﬁnity
a The dose of TMZ administered on pharmacokinetic sampling days (both i.v. and p.o.) was 150 mg/m
2 per day
b Model-based (least-squares) geometric mean
c Based on log-transformed data using ANOVA model extracting the effects due to treatment, sequence, subject within sequence and period
d Ratio of the mean value for i.v. to p.o. administration
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This pivotal exposure equivalence study was designed to
evaluate the bioavailability and safety of a 90-min intra-
venous infusion of temozolomide compared with an
equivalent oral dose. The goal was to establish comparable
systemic exposure (Cmax and AUC) to both temozolomide
and its active degradation product MTIC, following intra-
venous and oral administration. A crossover design was
used to decrease variability and the number of subjects
required to be enrolled. The crossover design used in this
study is analogous to the approach used in other studies
that have examined the exposure equivalence of intrave-
nous versus oral administration of chemotherapy agents
[13, 14]. In this study, 150 mg/m
2 temozolomide, the
approved dose of temozolomide for the ﬁrst cycle of
treatment in patients with recurrent glioma, including
refractory anaplastic astrocytoma (AA), was the dose
chosen for intravenous administration.
The intravenous dose was administered by a 90-min
infusion either on day 3 or day 4 in the middle of a 5-day
treatment course. Given that temozolomide and MTIC have
similar half-lives of approximately 1.8 h [4, 12, 15–17],
once-daily dosing on days 3 and 4 with a 24-h washout
period (corresponding to approximately 13 half-lives
between each dose) was sufﬁcient. In fact, predose (0 h)
concentrations for all PK-evaluable subjects in this study
were below the LLOQ for both temozolomide and MTIC.
The results of this study showed that a 90-min intrave-
nous infusion and an equivalent oral dose of temozolomide
met the exposure equivalence criteria based on the ratio of
mean AUC and Cmax for both temozolomide and MTIC.
Treatment-emergent adverse events were consistent with
those reported previously in patients with recurrent glioma
treated with oral temozolomide, except for local reactions
because of intravenous administration. Injection site reac-
tions were mostly mild and transient. No new safety con-
cerns emerged.
The intrasubject variability in AUC and Cmax for both
temozolomide and MTIC was low (CV B 13%; Table 3).
The intersubject variability in PK parameters for tem-
ozolomide was also low following both intravenous and
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Fig. 2 Meanplasmaconcentration–timeproﬁlesfortemozolomide(a)
and MTIC (b) following intravenous (i.v.) and oral (p.o.) administra-
tion. MTIC 5-(3-methyltriazen-1-yl)imidazole-4-carboxamide
Table 4 Treatment-emergent
adverse events (all grades)
occurring in C10% of subjects
excluding injection-related
events
p.o. oral, i.v. intravenous
a Reports treatment-emergent
adverse events not previously
reported on days 1 and 2
Days 3 and 4 only,
a n (%) Entire 28-day study
period, n (%)
p.o. i.v. Pooled Pooled
Any 8 (36) 10 (45) 14 (64) 21 (95)
Headache 3 (14) 4 (18) 6 (27) 9 (41)
Nausea 1 (5) 2 (9) 3 (14) 9 (41)
Constipation 0 1 (5) 1 (5) 6 (27)
Anemia 0 0 0 5 (23)
Vomiting 1 (5) 2 (9) 3 (14) 5 (23)
Dizziness 2 (9) 1 (5) 3 (14) 4 (18)
Leukopenia 0 0 0 4 (18)
Neutropenia 0 0 0 3 (14)
Thrombocytopenia 0 0 0 3 (14)
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123oral administration. This was not unexpected, as gastroin-
testinal absorption of temozolomide is rapid and bioavail-
ability is high. The intersubject variability in Cmax and
AUC for MTIC was higher than for temozolomide.
Nonetheless, systemic exposure to MTIC was similar
within individual subjects receiving intravenous versus oral
administration, and the intrasubject variability of MTIC
was low. The reason for the higher intersubject variability
in MTIC is unclear. However, the low intrasubject vari-
ability (8–13%) suggests that random issues with sample
handling were not a cause of the higher intersubject vari-
ability. In addition, the data were consistent across clinical
sites.
In the present study, the PK proﬁle of temozolomide
was independent of the route of administration. This is
consistent with previous studies evaluating the PK proﬁle
of oral temozolomide, which demonstrated that temozolo-
mide exhibits linear pharmacokinetics over the therapeutic
dose range [2, 4, 16–19] and that the PK proﬁle of tem-
ozolomide is independent of the route of administration
(i.e., intravenous, oral or hepatic intra-arterial infusion) [2].
Other studies have demonstrated that total body clearance
of temozolomide is linear [8, 16] and independent of dose
[16]. Moreover, the PK characteristics of temozolomide
have been shown to be independent of dosing schedules
[17]. The results of the present study are also consistent
with earlier studies that compared the PK of temozolomide
administered by intravenous, oral or intra-hepatic routes in
a few patients using different formulations [2]. Therefore,
the exposure equivalence data obtained from this study
allow for direct extrapolation across the range of thera-
peutically meaningful doses and administration schedules.
In conclusion, this study demonstrated the exposure
equivalence of a 90-min intravenous infusion with oral
administration of temozolomide. Intravenous administra-
tion of temozolomide was generally well tolerated. In
clinical practice, oral temozolomide is administered using a
variety of doses and schedules. Based on the data from this
study and the known PK characteristics of temozolomide,
intravenous administration would result in an equivalent
exposure compared with oral administration at any given
dose and schedule. Potential applications include use in
patients in whom oral administration is not feasible
because of the inability to swallow, nausea, vomiting or
impaired gastrointestinal absorption and in pediatric
patients.
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